Ontology highlight
ABSTRACT:
SUBMITTER: Kischel P
PROVIDER: S-EPMC6468599 | biostudies-literature | 2019 Mar
REPOSITORIES: biostudies-literature
Cancers 20190316 3
In the battle against cancer cells, therapeutic modalities are drastically limited by intrinsic or acquired drug resistance. Resistance to therapy is not only common, but expected: if systemic agents used for cancer treatment are usually active at the beginning of therapy (i.e., 90% of primary breast cancers and 50% of metastases), about 30% of patients with early-stage breast cancer will have recurrent disease. Altered expression of ion channels is now considered as one of the hallmarks of canc ...[more]